LENZ Therapeutics Q3 VIZZ sales jump 50% sequentially on strong demand

Overview

• U.S. pharmaceutical firm's Q3 VIZZ product sales rose 50% over prior quarter on growing demand

• Company posted Q3 net loss of $31.0 mln as launch investments drove higher expenses

• Company announced reorganization to cut 2027 operating expenses by over 50%

Outlook

• LENZ expects 2027 operating expenses of $70 mln to $75 mln, excluding stock-based compensation

• Company says strong sales momentum for VIZZ is continuing into Q4 as consumer awareness grows

• Company implementing reorganization in Q4 2026 to prioritize high-impact sales initiatives and improve efficiency

Result Drivers

• CONSUMER AWARENESS & TELEHEALTH - Co said higher Q3 sales were driven by broader consumer awareness and increased telehealth adoption

• TELEHEALTH CHANNEL - Telehealth prescribing option launched in July accounted for more than half of incremental Q3 prescriptions

• MARKETING CAMPAIGN - Nationwide TV and digital marketing campaign launched in July helped drive new patient acquisition

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for LENZ Therapeutics, Inc. is $10.00, about 217.5% above its October 27 closing price of $3.15

Reuters Recommended Reads

• Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth

• Oct 28 - Amarin Q3 revenue falls 20% on US pricing pressure

• Oct 28 - Vanda Pharmaceuticals Q3 revenue up 24% driven by Fanapt sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)